Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease

Official Title

Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease

Brief Summary

      In this study, the investigator plan to prescribe Methylprednisolone pulse therapy in
      Kawasaki disease patients with coronary artery lesions or aneurysm formation beyond acute
      stage to investigate the role for vasculitis of KD or regression of dilatation.
    

Detailed Description

      Kawasaki disease is the most common systemic vasculitis in children. Coronary artery
      aneurysms may develop in 20-25% of untreated patients. Intravenous immune globulin (IVIG) can
      reduce coronary-artery aneurysms to 3-5%. Numerous studies and clinical trials had pointed
      out that corticosteroid treatment (pulse therapy or not) could lower the incidence of
      coronary artery abnormality in high-risk KD patients. However, the therapeutic effect of
      corticosteroid in KD patients with aneurysm formation after acute stage was never mentioned.
      There is no effective treatment for aneurysm formation available in KD after acute stage.
      Methylprednisolone pulse therapy (MP pulse) was used for treatment of KD during acute stage
      since more than 20 years ago. MP pulse plus IVIG seems not benefit for KD patients but
      benefit for IVIG resistant KD patients or for high-risk group of CAL formation/ IVIG
      resistance group. MP pulse therapy is well document used in autoimmune disease vasculitis
      such as SLE, rheumatoid arthritis, dermatomyosis...etc. Taking together, MP pulse is
      effective and safe for KD patients during acute stage. In this study, the investigators plan
      to use MP pulse in KD patients with CAL or aneurysm formation beyond acute stage to
      investigate the role of vasculitis of KD or regression of dilatation.

      Methods: The investigators conducted a prospective study of methylprednisolone pulse therapy
      (MP pulse) for KD patients with coronary aneurysm or dilatation formation. The investigators
      will enroll these patients to receive methylprednisolone pulse (MP pulse, 30mg/kg, Max:1g/day
      for continue 3 days) for treatment. Together with other anti-inflammatory oral medicine
      including monteleukast, Dextromethorphan(DXM), prednisolone, and ketotifen as supplementary
      treatment.

      The specific aim of this study is the regression of coronary artery aneurysm after MP pulse
      therapy.

      Under the hypothesis and specific aim, the investigators plan to do in the following 3 years:

        1. During the 1st year, the investigators will enroll for 5-10 cases for safety surveys
           including blood pressure monitoring, inflammatory markers, liver function, renal
           function, electrolyte imbalance, growth problems as Phase I study.

        2. In the 2nd and 3rd year of this study, the investigators will enroll for 20-30 cases for
           an effective survey as Phase II study.

      Results from this study will help clinicians to treat aneurysm formation or coronary artery
      dilatation in KD patients and reduce the activity limitation of patients, reduce the medical
      resource in those patients. The investigators may provide the first treatment for aneurysm in
      KD.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Incidence of Treatment-Emergent Adverse Events and physical effects of Methylprednisolone pulse therapy in Kawasaki disease patients with coronary artery aneurysms

Secondary Outcome

 Echocardiography on the coronary artery lesion of Kawasaki disease

Condition

Mucocutaneous Lymph Node Syndrome

Intervention

Methylprednisolone Injection

Study Arms / Comparison Groups

 Participants treated with MP pulse
Description:  Selected participants will be given MP pulse treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

10

Start Date

April 15, 2020

Completion Date

August 31, 2023

Primary Completion Date

April 15, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Kawasaki disease patients with coronary artery dilation or aneurysm formation after
             acute stage (at lease 3 weeks after IVIG treatment)

        Exclusion Criteria:

          -  patients meet the contraindications of Methylprednisolone sodium succinate, e.g.,
             allergic to Methylprednisolone sodium succinate, premature infant, immune system
             related thrombocytopathy, immunodeficiency, any congenital diseases.
      

Gender

All

Ages

N/A - 17 Years

Accepts Healthy Volunteers

No

Contacts

, +886-7-7317123, [email protected]

Location Countries

Taiwan

Location Countries

Taiwan

Administrative Informations


NCT ID

NCT04509219

Organization ID

MP pulse in KD


Responsible Party

Sponsor

Study Sponsor

Chang Gung Memorial Hospital


Study Sponsor

, , 


Verification Date

May 2020